Table 1.
Patient characteristics by study group
| Characteristic | No. (%) of patients;* residence | p value | |
|---|---|---|---|
| Urban and suburban n = 219 |
Rural and remote n = 55 |
||
| Male sex | 145 (66) | 37 (67) | 0.88 |
| Age, yr, mean ± SD | 69 ± 13 | 63 ± 12 | 0.023 |
| Place of birth | < 0.001 | ||
| Canada | 70 (32) | 45 (82) | |
| Region not specified | 54 (25) | 5 (9) | |
| Western Europe | 46 (21) | 1 (2) | |
| Eastern Europe | 25 (11) | 3 (5) | |
| Asia | 15 (7) | 1 (2) | |
| Africa | 6 (3) | 0 (0) | |
| Central or South America | 3 (1) | 0 (0) | |
| Body mass index, kg/m2, mean ± SD | 25 ± 5 | 26 ± 4 | 0.70 |
| Charlson Comorbidity Index | 0.33 | ||
| Mild (1–2) | 8 (4) | 2 (4) | |
| Moderate (3–4) | 43 (19) | 16 (29) | |
| Severe (≥ 5) | 166 (74) | 37 (66) | |
| Signet ring cell carcinoma | 35 (16) | 12 (22) | > 0.99 |
| Tumour stage at diagnosis† | 0.003 | ||
| 0 | 2 (1) | 1 (2) | |
| I | 38 (17) | 7 (13) | |
| II | 48 (22) | 4 (7) | |
| III | 54 (25) | 27 (49) | |
| IV | 64 (29) | 11 (20) | |
| Clinical T stage | 0.30 | ||
| Tis | 2 (1) | 1 (2) | |
| T1 | 17 (8) | 4 (7) | |
| T2 | 29 (13) | 3 (5) | |
| T3 | 110 (50) | 33 (60) | |
| T4 | 47 (21) | 9 (16) | |
| Clinical N stage | 0.33 | ||
| N0 | 92 (42) | 18 (33) | |
| N+ | 111 (51) | 30 (55) | |
| Clinical M stage | 0.22 | ||
| M0 | 144 (66) | 40 (73) | |
| M1 | 60 (27) | 10 (18) | |
| Site of metastasis | 0.23 | ||
| Peritoneum | 23 (11) | 7 (13) | |
| Liver | 2 (1) | 0 (0) | |
| Nonregional lymph nodes | 6 (3) | 1 (2) | |
| Bone | 0 (0) | 1 (2) | |
| Neoadjuvant chemotherapy | 115 (53) | 34 (62) | 0.23 |
| Neoadjuvant radiotherapy | 8 (4) | 2 (4) | 1.00 |
M = distant metastasis; N = lymph node metastasis; SD = standard deviation; T = tumour extension.
*
Unless indicated otherwise.
†
According to the eighth edition of the American Joint Committee on Cancer Staging Manual.32